This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Gilead Sciences (GILD) Gets a Hold from Barclays

Tipranks - Tipranks - Sat Aug 15, 3:36AM CDT

In a report released today, Emily Field from Barclays maintained a Hold rating on Gilead Sciences, with a price target of $145.00.

Claim 55% Off TipRanks

Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and AbbVie. According to TipRanks, Field has an average return of 2.0% and a 46.01% success rate on recommended stocks.

In addition to Barclays, Gilead Sciences also received a Hold from RBC Capital’s Brian Abrahams in a report issued on August 4. However, on August 6, J.P. Morgan maintained a Buy rating on Gilead Sciences (NASDAQ: GILD).

See today’s best-performing stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $7.8 billion and a GAAP net loss of $10.5 billion. In comparison, last year the company earned a revenue of $7.08 billion and had a net profit of $1.96 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).